Provider: Nature Publishing Group
Content: application/x-research-info-systems
TY  - JOUR
AU  - Sawyers, C.
TI  - Targeted cancer therapy
JA  - Nature
PY  - 2004///
VL  - 432
SP  - 294
EP  - 297
M3  - 10.1038/nature03095
N1  - 10.1038/nature03095
UR  - http://dx.doi.org/10.1038/nature03095
ER  -

TY  - JOUR
AU  - Heinrich, M.C.
TI  - Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor
JA  - J. Clin. Oncol.
PY  - 2003///
VL  - 21
SP  - 4342
EP  - 4349
M3  - 10.1200/JCO.2003.04.190
N1  - 10.1200/JCO.2003.04.190
UR  - http://dx.doi.org/10.1200/JCO.2003.04.190
ER  -

TY  - JOUR
AU  - Shah, N.P.
TI  - Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
JA  - Cancer Cell
PY  - 2002///
VL  - 2
SP  - 117
EP  - 125
M3  - 10.1016/S1535-6108(02)00096-X
N1  - 10.1016/S1535-6108(02)00096-X
UR  - http://dx.doi.org/10.1016/S1535-6108(02)00096-X
ER  -

TY  - JOUR
AU  - Paez, J.G.
TI  - EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy
JA  - Science
PY  - 2004///
VL  - 304
SP  - 1497
EP  - 1500
M3  - 10.1126/science.1099314
N1  - 10.1126/science.1099314
UR  - http://dx.doi.org/10.1126/science.1099314
ER  -

TY  - JOUR
AU  - Pao, W.
TI  - EGF receptor gene mutations are common in lung cancers from [ldquo]never smokers[rdquo] and are associated with sensitivity of tumors to gefitinib and erlotinib
JA  - Proc. Natl. Acad. Sci. USA
PY  - 2004///
VL  - 101
SP  - 13306
EP  - 13311
M3  - 10.1073/pnas.0405220101
N1  - 10.1073/pnas.0405220101
UR  - http://dx.doi.org/10.1073/pnas.0405220101
ER  -

TY  - JOUR
AU  - Lynch, T.J.
TI  - Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
JA  - N. Engl. J. Med.
PY  - 2004///
VL  - 350
SP  - 2129
EP  - 2139
M3  - 10.1056/NEJMoa040938
N1  - 10.1056/NEJMoa040938
UR  - http://dx.doi.org/10.1056/NEJMoa040938
ER  -

TY  - JOUR
AU  - Pao, W.
TI  - Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
JA  - PLoS Med.
PY  - 2005///
VL  - 2
SP  - e73
M3  - 10.1371/journal.pmed.0020073
N1  - 10.1371/journal.pmed.0020073
UR  - http://dx.doi.org/10.1371/journal.pmed.0020073
ER  -

TY  - JOUR
AU  - Kobayashi, S.
TI  - EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
JA  - N. Engl. J. Med.
PY  - 2005///
VL  - 352
SP  - 786
EP  - 792
M3  - 10.1056/NEJMoa044238
N1  - 10.1056/NEJMoa044238
UR  - http://dx.doi.org/10.1056/NEJMoa044238
ER  -

TY  - JOUR
AU  - Shah, N.P.
TI  - Overriding imatinib resistance with a novel ABL kinase inhibitor
JA  - Science
PY  - 2004///
VL  - 305
SP  - 399
EP  - 401
M3  - 10.1126/science.1099480
N1  - 10.1126/science.1099480
UR  - http://dx.doi.org/10.1126/science.1099480
ER  -

TY  - JOUR
AU  - Kwak, E.L.
TI  - Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib
JA  - Proc. Natl. Acad. Sci. USA
PY  - 2005///
VL  - 102
SP  - 7665
EP  - 7670
M3  - 10.1073/pnas.0502860102
N1  - 10.1073/pnas.0502860102
UR  - http://dx.doi.org/10.1073/pnas.0502860102
ER  -

TY  - JOUR
AU  - Sanger, F.
AU  - Nicklen, S.
AU  - Coulson, A.R.
TI  - DNA sequencing with chain-terminating inhibitors
JA  - Proc. Natl. Acad. Sci. USA
PY  - 1977///
VL  - 74
SP  - 5463
EP  - 5467
M3  - 10.1073/pnas.74.12.5463
N1  - 10.1073/pnas.74.12.5463
UR  - http://dx.doi.org/10.1073/pnas.74.12.5463
ER  -

TY  - JOUR
AU  - van Ommen, G.J.
AU  - Bakker, E.
AU  - den Dunnen, J.T.
TI  - The human genome project and the future of diagnostics, treatment, and prevention
JA  - Lancet
PY  - 1999///
VL  - 354
IS  - Suppl 1
SP  - SI5
EP  - 10
ER  -

TY  - JOUR
AU  - Ronaghi, M.
AU  - Uhlen, M.
AU  - Nyren, P.
TI  - A sequencing method based on real-time pyrophosphate
JA  - Science
PY  - 1998///
VL  - 281
SP  - 363
EP  - 365
M3  - 10.1126/science.281.5375.363
N1  - 10.1126/science.281.5375.363
UR  - http://dx.doi.org/10.1126/science.281.5375.363
ER  -

TY  - JOUR
AU  - Margulies, M.
TI  - Genome sequencing in microfabricated high-density picolitre reactors
JA  - Nature
PY  - 2005///
VL  - 437
SP  - 376
EP  - 380
M3  - 10.1038/nature03959
N1  - 10.1038/nature03959
UR  - http://dx.doi.org/10.1038/nature03959
ER  -

TY  - JOUR
AU  - Janne, P.A.
TI  - A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening
JA  - Clin. Cancer Res.
PY  - 2006///
VL  - 12
SP  - 751
EP  - 758
M3  - 10.1158/1078-0432.CCR-05-2047
N1  - 10.1158/1078-0432.CCR-05-2047
UR  - http://dx.doi.org/10.1158/1078-0432.CCR-05-2047
ER  -

TY  - JOUR
AU  - Tsao, M.S.
TI  - Erlotinib in lung cancer - molecular and clinical predictors of outcome
JA  - N. Engl. J. Med.
PY  - 2005///
VL  - 353
SP  - 133
EP  - 144
M3  - 10.1056/NEJMoa050736
N1  - 10.1056/NEJMoa050736
UR  - http://dx.doi.org/10.1056/NEJMoa050736
ER  -

TY  - JOUR
AU  - Bell, D.W.
TI  - Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials
JA  - J. Clin. Oncol.
PY  - 2005///
VL  - 23
SP  - 8081
EP  - 8092
M3  - 10.1200/JCO.2005.02.7078
N1  - 10.1200/JCO.2005.02.7078
UR  - http://dx.doi.org/10.1200/JCO.2005.02.7078
ER  -

TY  - JOUR
AU  - Cortes-Funes, H.
TI  - Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients
JA  - Ann. Oncol.
PY  - 2005///
VL  - 16
SP  - 1081
EP  - 1086
M3  - 10.1093/annonc/mdi221
N1  - 10.1093/annonc/mdi221
UR  - http://dx.doi.org/10.1093/annonc/mdi221
ER  -

TY  - JOUR
AU  - Greulich, H.
TI  - Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants
JA  - PLoS Med.
PY  - 2005///
VL  - 2
SP  - e313
M3  - 10.1371/journal.pmed.0020313
N1  - 10.1371/journal.pmed.0020313
UR  - http://dx.doi.org/10.1371/journal.pmed.0020313
ER  -